uniQure Q3 net loss narrows 24% to $61.22 million
QURE•uniQure’s third-quarter 2026 net loss narrowed 24% year over year to $61.22 million, while revenue rose 40% to $5.2 million. Cash, cash equivalents and investment securities totaled $768.4 million, and the FDA granted priority review to AMT-130, with a May 1, 2027, target action date.
1. Quarterly results
uniQure’s third-quarter 2026 net loss narrowed 24% year over year to $61.22 million. Revenue increased 40% to $5.2 million due to higher license revenue. Cash, cash equivalents and investment securities totaled $768.4 million at September 30, which the company said was sufficient to fund projected operating expenses into 2030.
2. AMT-130 review
The FDA granted priority review to AMT-130 for Huntington’s disease, with a May 1, 2027, target action date.
